Silk Road Medical (NSDQ:SILK) this week posted fourth-quarter results that beat the revenue consensus on Wall Street and missed on earnings estimates.
The Sunnyvale, California-based stroke treatment company reported losses of -$14.7 million, or -42¢ per share, on sales of $28.3 million for the three months ended Dec. 31, 2021, for a bottom-line gain of 12.3% on sales growth of 33.75% compared with Q4 2020.
Earnings per share were 42¢, 7¢ behind The Street, where analysts were looking for sales of $25.91 million.
“Our team and physicians had a tremendous impact in 2021, performing nearly 14,000 cases and driving record annual revenue of $101.5 million,” president and CEO Erica Rogers said in a news release. “We drove measurable progress on regulatory and clinical fronts in anticipation of standard surgical risk approval in the U.S., entry into Japan and China, and development of our long-term pipeline, and we are well-positioned to continue establishing TCAR as the new standard of care in carotid artery disease through 2022 and beyond.”
Silk Road Medical projects revenue for fiscal year 2022 to be in the range of $126 million to $132 million.
Shares in SILK were up half a percentage point to $31.72 apiece in pre-market trading.